160 related articles for article (PubMed ID: 29542868)
1. Chemotherapy and terminal skeletal muscle differentiation in WT1-mutant Wilms tumors.
Royer-Pokora B; Beier M; Brandt A; Duhme C; Busch M; de Torres C; Royer HD; Mora J
Cancer Med; 2018 Apr; 7(4):1359-1368. PubMed ID: 29542868
[TBL] [Abstract][Full Text] [Related]
2. Classification of a frameshift/extended and a stop mutation in WT1 as gain-of-function mutations that activate cell cycle genes and promote Wilms tumour cell proliferation.
Busch M; Schwindt H; Brandt A; Beier M; Görldt N; Romaniuk P; Toska E; Roberts S; Royer HD; Royer-Pokora B
Hum Mol Genet; 2014 Aug; 23(15):3958-74. PubMed ID: 24619359
[TBL] [Abstract][Full Text] [Related]
3. Responsiveness of chemotherapy based on the histological type and Wilms' tumor suppressor gene mutation in bilateral Wilms' tumor.
Shibata R; Takata A; Hashiguchi A; Umezawa A; Yamada T; Hata J
Pathol Int; 2003 Apr; 53(4):214-20. PubMed ID: 12675764
[TBL] [Abstract][Full Text] [Related]
4. CTNNB1 mutations and overexpression of Wnt/beta-catenin target genes in WT1-mutant Wilms' tumors.
Li CM; Kim CE; Margolin AA; Guo M; Zhu J; Mason JM; Hensle TW; Murty VV; Grundy PE; Fearon ER; D'Agati V; Licht JD; Tycko B
Am J Pathol; 2004 Dec; 165(6):1943-53. PubMed ID: 15579438
[TBL] [Abstract][Full Text] [Related]
5. WT1-Mutant Wilms Tumor Progression Is Associated With Diverting Clonal Mutations of CTNNB1.
Duhme C; Busch M; Heine E; de Torres C; Mora J; Royer-Pokora B
J Pediatr Hematol Oncol; 2021 Mar; 43(2):e180-e183. PubMed ID: 31876779
[TBL] [Abstract][Full Text] [Related]
6. Clinical relevance of mutations in the Wilms tumor suppressor 1 gene WT1 and the cadherin-associated protein beta1 gene CTNNB1 for patients with Wilms tumors: results of long-term surveillance of 71 patients from International Society of Pediatric Oncology Study 9/Society for Pediatric Oncology.
Royer-Pokora B; Weirich A; Schumacher V; Uschkereit C; Beier M; Leuschner I; Graf N; Autschbach F; Schneider D; von Harrach M
Cancer; 2008 Sep; 113(5):1080-9. PubMed ID: 18618575
[TBL] [Abstract][Full Text] [Related]
7. A pathologic link between Wilms tumor suppressor gene, WT1, and IFI16.
Kim MK; Mason JM; Li CM; Berkofsky-Fessler W; Jiang L; Choubey D; Grundy PE; Tycko B; Licht JD
Neoplasia; 2008 Jan; 10(1):69-78. PubMed ID: 18231640
[TBL] [Abstract][Full Text] [Related]
8. Upregulation of c-MYC in WT1-mutant tumors: assessment of WT1 putative transcriptional targets using cDNA microarray expression profiling of genetically defined Wilms' tumors.
Udtha M; Lee SJ; Alam R; Coombes K; Huff V
Oncogene; 2003 Jun; 22(24):3821-6. PubMed ID: 12802290
[TBL] [Abstract][Full Text] [Related]
9. Two molecular subgroups of Wilms' tumors with or without WT1 mutations.
Schumacher V; Schuhen S; Sonner S; Weirich A; Leuschner I; Harms D; Licht J; Roberts S; Royer-Pokora B
Clin Cancer Res; 2003 Jun; 9(6):2005-14. PubMed ID: 12796362
[TBL] [Abstract][Full Text] [Related]
10. WT1 induces apoptosis through transcriptional regulation of the proapoptotic Bcl-2 family member Bak.
Morrison DJ; English MA; Licht JD
Cancer Res; 2005 Sep; 65(18):8174-82. PubMed ID: 16166292
[TBL] [Abstract][Full Text] [Related]
11. Wilms tumour histology is determined by distinct types of precursor lesions and not epigenetic changes.
Fukuzawa R; Anaka MR; Heathcott RW; McNoe LA; Morison IM; Perlman EJ; Reeve AE
J Pathol; 2008 Aug; 215(4):377-87. PubMed ID: 18484682
[TBL] [Abstract][Full Text] [Related]
12. Sequential WT1 and CTNNB1 mutations and alterations of beta-catenin localisation in intralobar nephrogenic rests and associated Wilms tumours: two case studies.
Fukuzawa R; Heathcott RW; More HE; Reeve AE
J Clin Pathol; 2007 Sep; 60(9):1013-6. PubMed ID: 17172473
[TBL] [Abstract][Full Text] [Related]
13. Clinically relevant subsets identified by gene expression patterns support a revised ontogenic model of Wilms tumor: a Children's Oncology Group Study.
Gadd S; Huff V; Huang CC; Ruteshouser EC; Dome JS; Grundy PE; Breslow N; Jennings L; Green DM; Beckwith JB; Perlman EJ
Neoplasia; 2012 Aug; 14(8):742-56. PubMed ID: 22952427
[TBL] [Abstract][Full Text] [Related]
14. Myogenesis in Wilms' tumors is associated with mutations of the WT1 gene and activation of Bcl-2 and the Wnt signaling pathway.
Fukuzawa R; Heathcott RW; Sano M; Morison IM; Yun K; Reeve AE
Pediatr Dev Pathol; 2004; 7(2):125-37. PubMed ID: 14994125
[TBL] [Abstract][Full Text] [Related]
15. RNA expression of the WT1 gene in Wilms' tumors in relation to histology.
Miwa H; Tomlinson GE; Timmons CF; Huff V; Cohn SL; Strong LC; Saunders GF
J Natl Cancer Inst; 1992 Feb; 84(3):181-7. PubMed ID: 1311774
[TBL] [Abstract][Full Text] [Related]
16. Identical genetic changes in different histologic components of Wilms' tumors.
Zhuang Z; Merino MJ; Vortmeyer AO; Bryant B; Lash AE; Wang C; Deavers MT; Shelton WF; Kapur S; Chandra RS
J Natl Cancer Inst; 1997 Aug; 89(15):1148-52. PubMed ID: 9262253
[TBL] [Abstract][Full Text] [Related]
17. Identification and analysis of mutations in WTX and WT1 genes in peripheral blood and tumor tissue of children with Wilms' tumor.
Wang H; Shen Y; Sun N; Jiang YP; Li ML; Sun L
Chin Med J (Engl); 2012 May; 125(10):1733-9. PubMed ID: 22800892
[TBL] [Abstract][Full Text] [Related]
18. Wilms tumor cells with WT1 mutations have characteristic features of mesenchymal stem cells and express molecular markers of paraxial mesoderm.
Royer-Pokora B; Busch M; Beier M; Duhme C; de Torres C; Mora J; Brandt A; Royer HD
Hum Mol Genet; 2010 May; 19(9):1651-68. PubMed ID: 20106868
[TBL] [Abstract][Full Text] [Related]
19. Ubiquitin specific protease 18 (Usp18) is a WT1 transcriptional target.
Shahidul Makki M; Cristy Ruteshouser E; Huff V
Exp Cell Res; 2013 Mar; 319(5):612-22. PubMed ID: 23291318
[TBL] [Abstract][Full Text] [Related]
20. WT1, WTX and CTNNB1 mutation analysis in 43 patients with sporadic Wilms' tumor.
Cardoso LC; De Souza KR; De O Reis AH; Andrade RC; Britto AC; De Lima MA; Dos Santos AC; De Faria PS; Ferman S; Seuánez HN; Vargas FR
Oncol Rep; 2013 Jan; 29(1):315-20. PubMed ID: 23117548
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]